Accordingly, our results showed that SIAIS562055 treatment markedly reduced the levels of RAC-GTP and RAS–GTP in BCR–ABL+ CML cells, continuously degraded SOS1, inhibited ERK phosphorylation, and retarded cell proliferation. This evidence concerns the gene MAPK1 and chronic myelogenous leukemia, BCR-ABL1 positive.